Clinical trials: Demyelinating Diseases
Invasive Group B Streptococcus (GBS) Disease
A Phase I, Randomized, Single-blind, Controlled, Single Center Study to Evaluate the Safety and Immunogenicity of a Dose Range of a Monovalent Glycoconjugate Antigen Vaccine of Group B Streptococcus in Healthy Women 18-40 Years of Age
The goals of the proposed study are to evaluate the safety, tolerability and immunogenicity of a GBS vaccine. Previous studies suggest that immune responses against GBS can protect humans from infection.
- Trial name
- NCT00657683
- Testing
- Monovalent GBS-CRM glycoconjugate vaccine
- Where
- Switzerland
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Multiple Sclerosis
Virtual Reality - Gamma Sensory Stimulation for Improving Fatigue in People With Multiple Sclerosis
This is a double-blind, parallel, randomized, sham-controlled pilot study evaluating the safety, feasibility, and efficacy of Gamma Sensory Stimulation (GSS) delivered via a Virtual Reality (VR) headset in individuals with…
- Trial name
- VR-GSS (NCT07310862)
- Testing
- Virtual Reality Gamma Sensory Stimulation
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Clarity Health Technologies, Inc
Refractory Lupus Nephritis, Myasthaenia Gravis
A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101
The purpose of this long-term follow-up (LTFU) study is to collect delayed adverse events (AEs) and understand the persistence of KYV-101 (autologous CAR T cell product; gene-modified product), in participants who have been…
- Conditions
- Refractory Lupus Nephritis, Myasthaenia Gravis, Stiff Person Syndrome, Rheumatoid Arthritis (RA)
- Trial name
- KYSA-4 (NCT07403188)
- Testing
- KYV-101
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Kyverna Therapeutics
Multiple Sclerosis, Relapsing-Remitting
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
The purpose of this prospective, multicenter, open-label, efficacy, and safety study is to assess the efficacy and safety of ocrelizumab in participants with Relapsing Remitting Multiple Sclerosis (RRMS) who have had a suboptimal…
- Trial name
- NCT02861014
- Testing
- Ocrelizumab
- Where
- 163 sites in Australia, Belgium and 15 more
- Volunteers
- 681 people
- Sponsor
- Hoffmann-La Roche
Spasticity With Multiple Sclerosis
Evaluation of the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis
This study will be conducted to evaluate the effect of multiple doses of nabiximols compared with placebo on a clinical measure of velocity-dependent muscle tone in the lower limbs (Lower Limb Muscle Tone-6 [LLMT-6]) in…
- Trial name
- RELEASE MSS5 (NCT04984278)
- Testing
- Nabiximols
- Where
- 30 sites in United States, Czechia and 3 more
- Volunteers
- 56 people
- Sponsor
- Jazz Pharmaceuticals
Ultomiris-exposed Pregnant/ Postpartum, Pregnancy
Study of Ultomiris® (Ravulizumab) Safety in Pregnancy
The primary objective of this study is to describe the frequency and characteristics of pregnancy outcomes and maternal complications among participants exposed to Ultomiris and to describe the frequency and characteristics of…
- Conditions
- Ultomiris-exposed Pregnant/ Postpartum, Pregnancy, Paroxysmal Nocturnal Hemoglobinuria (PNH), Atypical Hemolytic Uremic Syndrome (aHUS)
- Trial name
- NCT06312644
- Testing
- Ultomiris
- Where
- 7 sites in United States, Australia and 5 more
- Volunteers
- 75 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Canavan Disease
rAAV-Olig001-ASPA Gene Therapy for Treatment of Children With Typical Canavan Disease
Canavan Disease is a congenital white matter disorder caused by mutations to the gene encoding for aspartoacylase (ASPA). Expression of ASPA is restricted to oligodendrocytes, the sole white matter producing lineage in the brain.
- Trial name
- CAN-GT (NCT04833907)
- Testing
- rAAV-Olig001-ASPA, Levetiracetam, Prednisone
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Myrtelle Inc.
Chronic Inflammatory Demyelinating Polyneuropathy
An Expanded Access IND for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
This is an Individual Patient Expanded Access IND to evaluate the safety and preliminary efficacy of autologous HB-adMSCs for treating a single patient Chronic Inflammatory Demyelinating Polyneuropathy, CIDP.
- Trial name
- NCT04825626
- Testing
- HB-adMSCs
- Where
- United States
- Sponsor
- Hope Biosciences Research Foundation
Multiple Sclerosis
A Real-World Study of Ofatumumab in Multiple Sclerosis Patients in Germany and Japan
This study aims to evaluate the real-world persistence and adherence to ofatumumab (OMB) treatment in adult patients with relapsing multiple sclerosis (RMS).
- Trial name
- NCT07821411
- Where
- Switzerland
- Volunteers
- 5,000 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
A Study to Evaluate the Impact on Skin (Injection Site) Reactions of Taking an Antihistamine (Zyrtec®) or Placebo Prior to Daily Injections of Copaxone®.
This study is designed to compare injection skin (injection site) reactions when an antihistamine (Zyrtec®) or placebo is taken prior to performing daily Copaxone® injections.
- Trial name
- NCT00240032
- Testing
- glatiramer acetate injection with oral cetirizine hydrochloride
- Volunteers
- 80 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Relapsing Remitting Multiple Sclerosis
Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)
This is a Phase 2, randomized, rater-blinded, 5-arm, parallel-group trial that will test 4 doses of plovamer acetate against the active comparator Copaxone in subjects with Relapsing Remitting Multiple Sclerosis (RRMS).
- Trial name
- NCT01963611
- Testing
- Plovamer acetate 0.5 milligram (mg), Copaxone 20 mg, Plovamer acetate 3 mg
- Where
- 118 sites in United States, Bulgaria and 15 more
- Volunteers
- 255 people
- Sponsor
- EMD Serono
Asthma
A Study of the Effect of FTY720 on Pulmonary Function in Patients With Moderate Asthma
This study will evaluate the effect of FTY720 on the lung function of patients with moderate asthma
- Trial name
- NCT00785083
- Testing
- FTY720
- Where
- United Kingdom
- Volunteers
- 36 people
- Sponsor
- Novartis
All Diagnosed Health Conditions, ADD/ADHD
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
We are the missing link in clinical trials, connecting patients and researchers seamlessly and conveniently using a mobile health platform to advance medical research.
- Conditions
- All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis
- Trial name
- NCT01931644
- Where
- United States
- Volunteers
- 17,667 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Multiple Sclerosis
Survey Among Healthcare Professionals and MS Patients to Assess Their Understanding of RMP Materials
Survey to be completed independently by HCPs (neurologists treating patients with MS and MS specialist nurses) and patients/caregivers.
- Trial name
- NCT05301907
- Where
- Switzerland
- Volunteers
- 335 people
- Sponsor
- Novartis Pharmaceuticals
Relapsing-Remitting Multiple Sclerosis (RRMS)
Brimonidine Tartrate for the Treatment of Injection Related Erythema
The primary objective of this study is to evaluate the Injection Related Erythema (IRE) mitigation effect of a single administration of brimonidine tartrate in comparison with a vehicle gel (placebo).
- Trial name
- BRITE (NCT02568111)
- Testing
- peginterferon beta-1a, brimonidine tartrate, Vehicle Gel
- Sponsor
- Biogen
Chronic Inflammatory Demyelinating Polyneuropathy
Safety, Tolerability, and Efficacy of NVG-2089 in Participants With CIDP
The purpose of the study is to evaluate the safety of NVG-2089 and to evaluate how well patients respond to this investigational treatment. NVG-2089 is a new drug that is being developed for treating patients with CIDP.
- Trial name
- INVGOR (NCT07027111)
- Testing
- NVG-2089
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Nuvig Therapeutics, Inc.
Multiple Sclerosis
Clinical Trial Assessing Temelimab Following Rituximab Treatment in Patients With Relapsing Forms of Multiple Sclerosis
Randomized, double-blind, placebo-controlled Phase IIa clinical study, assessing safety, tolerability, pharmacodynamic effects and pharmacokinetics of temelimab, administered at three different dose levels (18 mg/kg or 36 mg/kg…
- Trial name
- ProTEct-MS (NCT04480307)
- Testing
- temelimab 18 mg/kg, temelimab 36 mg/kg, temelimab 54 mg/kg
- Where
- Sweden
- Volunteers
- 41 people
- Sponsor
- GeNeuro Innovation SAS
Guillain-Barré Syndrome
Phase III Clinical Trial of NPB-01 in Patients With Guillain-Barré Syndrome
Patients diagnosed with Guillain-Barré syndrome were confirmed based on the diagnostic criteria for Guillain-Barré syndrome. Patients who meet all inclusion criteria and do not conflict with the exclusion criteria will receive…
- Trial name
- NCT02221271
- Testing
- NPB-01
- Where
- Japan
- Volunteers
- 22 people
- Sponsor
- Nihon Pharmaceutical Co., Ltd
Neurological Diseases or Conditions, Dementia of Alzheimer Type
An Observational Study of Patients Living With Chronic Neurological Diseases
TARGET-NEURO is an observational research study to conduct a comprehensive review of outcomes for patients living with chronic neurological diseases: Alzheimer's disease and related dementia (ADRD), mild cognitive impairment…
- Conditions
- Neurological Diseases or Conditions, Dementia of Alzheimer Type, Alzheimer Disease, Mild Cognitive Impairment
- Trial name
- NCT05796037
- Volunteers
- 1,500,000 people
- Sponsor
- Target PharmaSolutions, Inc.
Multiple Sclerosis
Single-Dose Study of a New Formulation of BIIB061
The primary objective of the study is to assess the pharmacokinetic (PK) profile of BIIB061 in the new oral formulation in the fasted state in healthy male and female volunteers.
- Trial name
- NCT02521545
- Testing
- BIIB061
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Biogen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.